Cobicistat
Generic name
Cobicistat
Brand name
ATC Code
V03AX03
- Dosages
- Side effects in children
- Warnings & precautions in children
- Contra-indications in children
-
Interactions - PK
- Renal impairment
- References
Pharmacokinetics in children
Geen informatie over farmacokinetische parameters bij kinderen beschikbaar .
dose recommendation of formulary compared to licensed use (on-label versus off-label)
Off-label
Licensed use Licensed useAvailable formulations
Tablet 150 mg
Dosages
Renal impaiment in children > 3 months
GFR ≥10 ml/min/1.73m2: Dose adjustment not required.
GFR <10 ml/min/1.73m2: A general recommendation on dose adjustment cannot be provided.
The complete list of all undesirable drug reactions can be found in the national Summary of Product Characteristics (SmPC) – click here
Adult Side Effects
Bij therapie in combinatie met atazanavir: Zeer vaak (> 10%): misselijkheid. Geelzucht.
Vaak (1–10%): droge mond, braken, dyspepsie, buikpijn, flatulentie, diarree. Toegenomen eetlust, hyperglykemie. Hyperbilirubinemie. Hoofdpijn, duizeligheid, slaperigheid, slapeloosheid, vermoeidheid, ongewone dromen, dysgeusie. Huiduitslag.
Soms (0,1–1%): koorts, asthenie. Depressie. Proteïnurie, hematurie, nefrolithiase. Myalgie. Jeuk.
The complete list of all contra-indications can be found in the national Summary of Product Characteristics (SmPC) – click here
Contra-indications
No information available on specific contra indications in children.
The complete list of all warnings and precautions can be found in the national Summary of Product Characteristics (SmPC) – click here
Warnings & precautions
No information available on specific warnings and precautions in children.
Interactions
The complete list of all interactions can be found in the national Summary of Product Characteristics (SmPC) – click here
ALL OTHER THERAPEUTIC PRODUCTS
This pages provides a list of drugs from the same ATC class for comparison. This does not necessarily mean that these drugs are interchangeable.
| Antidotes | ||
|---|---|---|
| V03AB27 | ||
| V03AB16 | ||
| V03AB24 | ||
| V03AB25 | ||
| V03AB33 | ||
| V03AB17 | ||
| V03AB15 | ||
| V03AB13 | ||
| V03AB19 | ||
| V03AB14 | ||
| V03AB06 | ||
| V03AB35 | ||
| Iron chelating agents | ||
|---|---|---|
| V03AC03 | ||
| V03AC02 | ||
| V03AC01 | ||
| Drugs for treatment of hyperkalemia and hyperphosphatemia | ||
|---|---|---|
| V03AE07 | ||
| V03AE01 | ||
| V03AE02 | ||
| V03AE01 | ||
| Detoxifying agents for antineoplastic treatment | ||
|---|---|---|
| V03AF03 | ||
| V03AF01 | ||
| V03AF07 | ||
| Drugs for treatment of hypoglycemia | ||
|---|---|---|
| V03AH01 | ||
| DETOXIFYING AGENTS FOR ANTINEOPLASTIC TREATMENT | ||
|---|---|---|
| V03AF03 | ||
| V03AF01 | ||
| V03AF07 | ||
References
- Panel on Antiretroviral Therapy and Medical Management of HIV-Infected Children., Guideline for the use of Antiretroviral agents in pediatric HIV infection, www.aidsinfo.nig.gov/contentfiles/lvguidelines/pediatricguidelines, Geraadpleegd 14 feb 2017
- Bamford, A., et al (PENTA Steering Committee) (2015), Paediatric European Network for Treatment of AIDS (PENTA) guidelines for treatment of paediatric HIV-1 infection 2015: optimizing health in preparation for adult life. , HIV Med, 2015, doi:10.1111/hiv.12217
- Bamford, A., et al (PENTA Steering Committee) (2015), Paediatric European Network for Treatment of AIDS (PENTA) guidelines for treatment of paediatric HIV-1 infection 2015: optimizing health in preparation for adult life., HIV Med, 2015, doi:10.1111/hiv.12217
Changes
Therapeutic Drug Monitoring
Overdose
